Scotiabank Maintains Sector Outperform on Biogen, Lowers Price Target to $244
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst George Farmer maintains a Sector Outperform rating on Biogen (NASDAQ:BIIB) but lowers the price target from $275 to $244.
August 02, 2024 | 4:31 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Scotiabank analyst George Farmer maintains a Sector Outperform rating on Biogen but lowers the price target from $275 to $244.
The maintained Sector Outperform rating suggests continued confidence in Biogen's performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100